{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:03:51Z","timestamp":1789758231460,"version":"4.0.1"},"reference-count":21,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Type 1 diabetes mellitus (T1D) is a multifactorial autoimmune disease characterized by the selective destruction of pancreatic insulin-producing beta cells due to the aberrant activation of different immune effector cells (reviewed (rev [...]<\/jats:p>","DOI":"10.3390\/ijms24119220","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T02:58:48Z","timestamp":1684983528000},"page":"9220","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Advances in Immunotherapeutic Approaches to Type 1 Diabetes"],"prefix":"10.3390","volume":"24","author":[{"given":"Annamaria","family":"Cudini","sequence":"first","affiliation":[{"name":"Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-9754","authenticated-orcid":false,"given":"Alessandra","family":"Fierabracci","sequence":"additional","affiliation":[{"name":"Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.autrev.2012.12.003","article-title":"The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity","volume":"12","author":"Gianchecchi","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4239\/wjd.v6.i3.380","article-title":"Type 1 diabetes: A predictable disease","volume":"6","author":"Simmons","year":"2015","journal-title":"World J. Diabetes"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00125-017-4308-1","article-title":"Early prediction of autoimmune (type 1) diabetes","volume":"60","author":"Regnell","year":"2017","journal-title":"Diabetologia"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rapini, N., Schiaffini, R., and Fierabracci, A. (2020). Immunotherapy Strategies for the Prevention and Treatment of Distinct Stages of Type 1 Diabetes: An Overview. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062103"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cabello-Olmo, M., Ara\u00f1a, M., Radichev, I., Smith, P., Huarte, E., and Barajas, M. (2019). New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194789"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMoa043980","article-title":"Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes","volume":"352","author":"Keymeulen","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1097\/TP.0b013e31818fe448","article-title":"Long Term Insulin Independence and Improvement in Insulin Secretion after Supplemental Islet Infusion under Exenatide and Etanercept","volume":"86","author":"Faradji","year":"2008","journal-title":"Transplantation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.297.14.1568","article-title":"Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus","volume":"297","author":"Voltarelli","year":"2007","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2337\/db14-0295","article-title":"Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in New-Onset Type 1 Diabetes: A Multicenter Analysis","volume":"63","author":"Franek","year":"2014","journal-title":"Diabetes"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ni.3002","article-title":"Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications","volume":"15","author":"Wang","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3389\/fimmu.2017.01125","article-title":"Chimeric Antigen Receptor-Redirected Regulatory T Cells Suppress Experimental Allergic Airway Inflammation, a Model of Asthma","volume":"8","author":"Skuljec","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Del Chierico, F., Conta, G., Matteoli, M.C., Fierabracci, A., Reddel, S., Macari, G., Gardini, S., Guarrasi, V., Levi Mortera, S., and Marzano, V. (2022). Gut Microbiota Functional Traits, Blood pH, and Anti-GAD Antibodies Concur in the Clinical Characterization of T1D at Onset. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810256"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lebenthal, Y., Brener, A., Hershkovitz, E., Shehadeh, N., Shalitin, S., Lewis, E.C., Elias, D., Haim, A., Barash, G., and Loewenthal, N. (2019). A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Alpha-1 Antitrypsin (AAT) (Glassia\u00ae) in the Treatment of Recent-Onset Type 1 Diabetes. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20236032"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Dedda, C.D., Vignali, D., Piemonti, L., and Monti, P. (2019). Pharmacological Targeting of GLUT1 to Control Autoreactive T Cell Responses. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194962"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.4049\/jimmunol.152.6.2660","article-title":"Changes in glucose transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin","volume":"152","author":"Chakrabarti","year":"1994","journal-title":"J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kavanagh Williamson, M., Coombes, N., Juszczak, F., Athanasopoulos, M., Khan, M.B., Eykyn, T.R., Srenathan, U., Taams, L.S., Dias Zeidler, J., and Da Poian, A.T. (2018). Upregulation of Glucose Uptake and Hexokinase Activity of Primary Human CD4+ T Cells in Response to Infection with HIV-1. Viruses, 10.","DOI":"10.3390\/v10030114"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ludvigsson, J. (2020). Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051598"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s11892-013-0415-7","article-title":"Antigen-Based Vaccination and Prevention of Type 1 Diabetes","volume":"13","author":"Harrison","year":"2013","journal-title":"Curr. Diab. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Orban, T., Orban, N.T., Jalahej, H., and Daubeney, P.E.F. (2020). A Novel Quantitative Approach to Staging and Assessing Recovery from Type 1 Diabetes Mellitus: The Type 1 Diabetes Mellitus Metabolic Recovery Index. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030992"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Thompson, P.J., Shah, A., Apostolopolou, H., and Bhushan, A. (2019). BET Proteins Are Required for Transcriptional Activation of the Senescent Islet Cell Secretome in Type 1 Diabetes. Int. J. Mol. Sci., 20.","DOI":"10.1101\/736231"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/11\/9220\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:41:32Z","timestamp":1760125292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/11\/9220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms24119220"],"URL":"https:\/\/doi.org\/10.3390\/ijms24119220","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]}}}